What is NRXP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.10B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NRXP?

P/E (TTM) is n/a and 52-week range is $1.62 to $5.05 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NRXP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NRXP?

The company profile lists revenue (TTM) near $4M, net income (TTM) near -$2.70B, EPS (TTM) near -$0.74 when available from the market-data feed. Figures are informational and may lag live markets.

Where is NRX Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Wilmington, Delaware, US, 43.3M shares outstanding, ISIN US6294442099 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

NRX Pharmaceuticals Inc

$NRXP

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware and currently employs 29 full-time employees. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

Employees

Website

www.nrxpharma.com

IPO

2017-11-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US6294442099

Headquarters

Wilmington, Delaware, US

Shares outstanding

43.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

27.13%

Browse other companiesFree AI scores and summaries for more stocks